Please assess the completion status of the following clinical trial:

Trial Title: Neurokinin Receptor Antagonist Associated to Ondansetron in PONV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* high risk patients for nausea and vomiting~Exclusion Criteria:~* cardiovascular disease, or hypersensibility to any of the drugs involved in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- aprepitant (Type: EXPERIMENTAL): aprepitant 80 mg one hour before surgery
- placebo (Type: PLACEBO_COMPARATOR): oral placebo one hour before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).